{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T01:28:55Z","timestamp":1772674135701,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Astellas"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.diabres.2014.07.020","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T12:16:26Z","timestamp":1406376986000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"106","author":[{"given":"Takeshi","family":"Kadokura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsunori","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Utsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Kazuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuro","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Smulders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2014.07.020_bib0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","article-title":"Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus","volume":"70","author":"Neumiller","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2014.07.020_bib0010","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.diabres.2014.07.020_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2014.07.020_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.diabres.2014.07.020_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13340-011-0037-8","article-title":"Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects","volume":"2","author":"Kadokura","year":"2011","journal-title":"Diabetol Int"},{"key":"10.1016\/j.diabres.2014.07.020_bib0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/BF03256922","article-title":"Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects","volume":"31","author":"Veltkamp","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.diabres.2014.07.020_bib0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/jdi.12156","article-title":"Randomized, placebo-controlled, double-blind glycemic control trial of novel SGLT2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus","volume":"5","author":"Kashiwagi","year":"2014","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2014.07.020_bib0040","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/dia.2011.0012","article-title":"Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus","volume":"13","author":"Schwartz","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2014.07.020_bib0045","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2337\/dc12-1503","article-title":"Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2014.07.020_bib0050","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2014.07.020_bib0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13340-012-0069-8","article-title":"International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values","volume":"3","author":"Kashiwagi","year":"2012","journal-title":"Diabetol Int"},{"key":"10.1016\/j.diabres.2014.07.020_bib0060","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/clinchem.2003.024802","article-title":"IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study","volume":"50","author":"Hoelzel","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.diabres.2014.07.020_bib0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1373\/clinchem.2007.097402","article-title":"The IFCC reference measurement system for HbA1c: a 6-year progress report","volume":"54","author":"Weykamp","year":"2008","journal-title":"Clin Chem"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714003143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822714003143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T06:24:21Z","timestamp":1565677461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822714003143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0168822714003143"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2014.07.020","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2014.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}